Docon Technologies Sells 9.9% Stake in Thyrocare for Rs 986 Crore

Docon Technologies, a leading promoter of Thyrocare Technologies Ltd, has offloaded a significant 9.9% stake in the diagnostic chain for approximately Rs 986 crore. The transaction occurred through a series of bulk and block deals on Thursday, impacting both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).

Details of the Stake Sale

The sale involved the disposal of 1,57,69,696 equity shares, significantly reducing Docon's holding in Thyrocare from 60.92% to 51.02%. Shares were traded in a price range of Rs 624 to Rs 631.71 per share. This strategic divestment drew participation from a range of institutional investors, including HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, and Aditya Birla Sun Life Mutual Fund.

Notably, more than 1.31 crore shares were exchanged through block deals, with an additional 10 lakh shares transacted via bulk deals on the NSE. Furthermore, 16.01 lakh shares were sold through a bulk deal on the BSE. The robust involvement of institutional investors reflects the attractiveness of Thyrocare's business model and its market potential.

Investor Participation and Market Reaction

Besides mutual funds, insurance companies like Kotak Mahindra Life Insurance Company and Tata AIA Life Insurance also participated. Global financial entities such as Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the Kuwait Investment Authority were key players in the block deals on the NSE. This diverse range of investors underscores the confidence in Thyrocare's future prospects.

Following the announcement of the stake sale, Thyrocare Technologies' shares saw an uptick, rising nearly 3% to Rs 621.95 on the NSE and over 2% to Rs 622 on the BSE. This positive market response highlights the perceived value of the company despite the significant share offloading by Docon.

Previous Transactions and Strategic Implications

This recent transaction follows a similar move by Docon last October, where it sold a 10% stake in Thyrocare for Rs 667 crore. Such strategic sales may indicate a broader restructuring or reallocation of capital by Docon Technologies, although specific future plans have not been disclosed.

The participation of numerous high-profile institutional investors in this transaction suggests a strong belief in the long-term growth trajectory of Thyrocare Technologies. As the company continues to expand its footprint in the diagnostics sector, these investments could prove pivotal in supporting its growth strategies.